Ardelyx (ARDX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Ardelyx (ARDX) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ardelyx's market cap?
Ardelyx (ARDX) has a market capitalization of approximately
What is Ardelyx's P/E ratio?
Ardelyx's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 8.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ardelyx?
Ardelyx runs a net profit margin of -13.6%, a gross margin of 91.9%, and an operating margin of -8.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ardelyx generate?
Ardelyx reported revenue of $407M for fiscal year 2025, with net income of -$62M and earnings per share (EPS) of -0.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ardelyx pay a dividend?
Ardelyx does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Ardelyx financially healthy?
Ardelyx carries a debt-to-equity ratio of 1.40x and a current ratio of 3.49x, with a market beta of 0.60. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ardelyx a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ardelyx (ARDX) the key facts are: market cap
Track Ardelyx's full fundamentals live
Get Ardelyx's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.